Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

ClinicalTrials.gov ID: NCT06819007

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06819007. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Study identification

NCT ID: NCT06819007
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 582 participants

Conditions and interventions

Conditions

Ovarian Cancer

Interventions

Trastuzumab Deruxtecan Drug
Bevacizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 19, 2025 (Actual)
Primary completion: Nov 1, 2028 (Estimated)
Completion: Jan 31, 2032 (Estimated)
Last update posted: Oct 28, 2026

2025 – 2032

United States locations

U.S. sites: 33
U.S. states: 21
U.S. cities: 29

Facility	City	State	ZIP	Site status
Disney Family Cancer Center	Burbank	California	91505	Recruiting
Scripps Clinic	La Jolla	California	92037	Recruiting
Palo Alto Medical Foundation	Palo Alto	California	94301	Recruiting
Broward Health Medical Center	Fort Lauderdale	Florida	33316	Recruiting
Jupiter Medical Center	Jupiter	Florida	33458	Recruiting
Mount Sinai Medical Center	Miami Beach	Florida	33140	Recruiting
AdventHealth Cancer Institute	Orlando	Florida	32804	Recruiting
Woman's Care FL	St. Petersburg	Florida	33713	Recruiting
Nancy N. & J.C Lewis Cancer & Research Pavillion- St. Josephs/ Candler Health System	Savannah	Georgia	31405	Recruiting
Endeavor Health Evanston Kellogg Cancer Care Center	Evanston	Illinois	60201	Recruiting
Indiana University	Indianapolis	Indiana	46202	Recruiting
Trials365 LLC	Shreveport	Louisiana	71103	Recruiting
Greater Baltimore Medical Center	Towson	Maryland	21204	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Trinity Health St. Joseph Mercy Ann Arbor	Ann Arbor	Michigan	48106	Recruiting
Corewell Health	Grand Rapids	Michigan	49503	Recruiting
Minnesota Oncology Hematology PA	Minneapolis	Minnesota	55404	Recruiting
St. Vincent Gynecologic Oncology	Billings	Montana	59102	Recruiting
Valley Health System	Paramus	New Jersey	07652	Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	New York	10016	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Columbia University	New York	New York	10032	Recruiting
UNC Hospital	Chapel Hill	North Carolina	27599	Recruiting
Miami Valley Hospital South	Centerville	Ohio	45459	Recruiting
Legacy Medical Group Gynecologic Oncology	Portland	Oregon	97210	Recruiting
Providence Cancer Center Oncology	Portland	Oregon	97213	Recruiting
St. Lukes University Health Network	Bethlehem	Pennsylvania	18015	Recruiting
Ann B Barshinger Cancer Institute	Lancaster	Pennsylvania	17601	Recruiting
Avera Medical Group Gynecologic	Sioux Falls	South Dakota	57105	Recruiting
Sarah Cannon Research Institute (Oncology Associates of Oregon PC)	Nashville	Tennessee	37203	Recruiting
Utah Cancer Specialists Network	Salt Lake City	Utah	84106	Recruiting
University of Wisconsin	Madison	Wisconsin	53792	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 199 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06819007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 28, 2026 · Synced Nov 15, 2026